Navigation Links
MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices

WAYNE, N.J., Dec. 16 /PRNewswire/ -- MAQUET Cardiovascular LLC, a leading provider of cardiovascular technologies, today announced that it has signed a three-year single source provider contract with Novation, the industry's leading supply contracting company, for MAQUET's market-leading VASOVIEW Endoscopic Vessel Harvesting (EVH) Systems. The VASOVIEW products assist healthcare providers in obtaining veins for repair of blocked coronary arteries using only small incisions. This allows for faster healing, less postoperative pain and scarring and potentially reduced risk of complications, such as infection, compared with open vein retrieval methods.

"Receiving Novation's single source provider contract for our EVH products affirms MAQUET's role as the industry leader in EVH technology," said Raoul Quintero, President of MAQUET Cardiovascular U.S. Sales LLC. "Our team is looking forward to developing partnerships with the members Novation serves. This agreement will provide the critical EVH products and support that benefit the cardiac surgery teams who will use them, as well as their patients who are undergoing a more minimally invasive surgical procedure."

The agreement was effective on November 1, 2009, and runs through September 2012. Under the terms of the agreement, MAQUET Cardiovascular will be the exclusive provider of EVH devices and supplies to the members of VHA Inc., University HealthSystem Consortium (UHC) and Provista.

"Following a rigorous review by our technology assessment and contracting teams, MAQUET met all of our process requirements for the single source contract," said Scott Crandall, Senior Director, Contract Services Cardiology at Novation. "This contract supports our continued service to members to access the highest quality technology that will best meet their needs. We are pleased to add this to the agreements we hold with MAQUET Cardiovascular."

About Endoscopic Vein Harvesting

In endoscopic vessel harvesting (EVH), a healthy blood vessel, such as the saphenous vein from the leg or the radial artery from the arm, is removed through a small incision for use during coronary artery bypass graft (CABG) surgery to bypass a blockage in the heart. Today, EVH is considered the standard of care and has been shown to reduce postoperative pain, recovery time, infection rates and scarring, and allow patients to walk sooner and recover more quickly than conventional open vein harvesting surgery. Since the first system for EVH was launched in 1997, more than 1 million procedures using VASOVIEW products have been performed.

About Novation

Founded in 1998, Novation is the leading health care supply contracting company for more than 25,000 members of VHA Inc. and the University HealthSystem Consortium (UHC), two national health care alliances and nearly 15,000 members of Provista, LLC. Novation offers its customers contract development and management, supply chain data and measurement, and industry knowledge and advocacy. Based in Irving, Texas, Novation develops and manages competitive contracts with more than 500 suppliers. VHA, UHC and Provista members used Novation contracts to purchased nearly $35.7 billion in 2008.

About MAQUET Cardiovascular

MAQUET Cardiovascular is a leader in providing innovative products for cardiac surgery, vascular intervention and cardiac support to hospitals and clinics and the cardiac surgeons, interventional cardiologists, perfusionists and other healthcare professionals who care for patients with cardiovascular disease. MAQUET Cardiovascular is focused on providing clinicians with future-oriented technology that fits into their daily practice and that improves the therapeutic management of patients. MAQUET Cardiovascular continues to invest in the development of innovative technologies and solutions that advance clinical practice, improve patient outcomes and enhance quality of life.

MAQUET Cardiovascular was formed in 2003 when MAQUET combined its existing Cardiopulmonary business with Jostra's equipment and consumables for open heart surgery and Siemens Life Support Systems that GETINGE acquired in 2003. In 2008, it added the Cardiac Surgery and Vascular Interventions businesses that GETINGE acquired from Boston Scientific and Guidant in 2008. In 2009, it added the cardiac assist businesses that GETINGE acquired from Datascope. MAQUET Cardiovascular provides healthcare professionals with products in four business units: Cardiopulmonary (perfusion products), Cardiac Surgery (clampless beating heart and endoscopic vessel harvesting), Vascular Interventions (grafts for vascular surgery), and Cardiac Assist (intra-aortic balloon counterpulsation therapy).


The MAQUET Group is the global market leader for Medical Systems, focusing on the Operating Room (OR) and Intensive Care Unit (ICU). The integrated products of MAQUET are specially designed to deliver optimal clinical treatment and therapy concepts within acute care hospitals. MAQUET provides innovative medical solutions from three divisions:

  • Cardiovascular with products for cardiac assist (intra-aortic balloon counterpulsation therapy), coronary artery bypass surgery, aneurysm and vascular repair, peripheral interventions and extracorporeal circulation.
  • Critical Care for intensive care ventilators and anesthesia machines
  • Surgical Workplaces for OR tables, lights and ceiling service units, prefabricated OR and ICU suites, as well as telemedicine for the OR integration.

MAQUET is a subsidiary of the publicly-listed Swedish GETINGE GROUP, a company with over $2.8 billion in revenues (2008 fiscal year) and 12,800 employees worldwide. In 2008 MAQUET itself generated pro-forma revenues (including the acquisition of Datascope Corp.) of over $1.4 billion. The company now has 5,000 employees in 35 international sales and service organizations, as well as a network of more than 200 sales representatives.

MAQUET - The Gold Standard.

SOURCE MAQUET Cardiovascular LLC

SOURCE MAQUET Cardiovascular LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. MAQUET Cardiovascular Receives Guaranteed Two-Year Sole Source Contract From Novation for Beating Heart Surgical Devices
2. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
3. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation
4. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
5. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
6. Cardiologists Tackle Next Frontier in Cardiovascular Disease
7. Enrollment of Women in Cardiovascular Trials Fails to Meet Current Federal Mandates
8. Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients with Diabetes
9. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
10. New Data from the Framingham Heart Study Supports PAT Technology to Diagnose Early Cardiovascular Disease
11. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
Post Your Comments:
(Date:11/26/2015)... UTRECHT , Países Bajos, November 26, 2015 /PRNewswire/ ... con la terapia fotodinámica de Bremachlorin para el cáncer ... combina la inmunoterapia con la terapia fotodinámica de Bremachlorin ... Un nuevo enfoque combina la inmunoterapia con la ...   Clinical Cancer Research . --> ...
(Date:11/26/2015)... North Carolina , 26 november 2015 ... Inc. (AAIPharma/CML) kondigt de geplande investering aan ... uitbreiding van de laboratoria en het mondiale ... . De uitbreiding zal resulteren in extra ... wordt voldaan aan de groeiende behoeften van ...
(Date:11/26/2015)... 26, 2015 --> ... approach blends immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer. ... blends immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer. ... blends immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer. ... found that immunotherapy can be efficiently combined with photodynamic ...
Breaking Medicine Technology:
(Date:11/25/2015)... BROOK, Ill. (PRWEB) , ... November 25, 2015 ... ... larger and potentially more aggressive than those found on mammography, according to a ... MRI findings of additional cancers not seen on mammography may necessitate a change ...
(Date:11/25/2015)... ... November 25, 2015 , ... Finnleo, a leader in the traditional and far-infrared ... traditional and far-infrared saunas. , For traditional saunas, Finnleo is offering ... sauna wood, and Finnleo uses only European Grade A Nordic White Spruce from sustainably ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dr. John Pierce, Medical ... more about hair loss treatment with the Capillus272™ Pro laser therapy cap. FDA cleared ... thicker and fuller hair, without the need for surgery, prescription pills, or topical foams. ...
(Date:11/25/2015)... ... ... For the first time, Vitalalert is donating half of its earnings to ... between the two groups began in 2014 with Vitalalert pledging a portion of every ... founded in 1954 and is an international Christian-based health organization whose mission is to ...
(Date:11/25/2015)... ... ... Dental professionals who would like to become more proficient on their knowledge of ... Advanced Implant Mentoring (AIM) CE course. Courses will be held on December 3rd, 4th ... Implant Mentoring (AIM), Dr. Iacobelli and Dr. D’Orazio are proud to announce that individuals ...
Breaking Medicine News(10 mins):